![](/img/cover-not-exists.png)
PCN140 COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB COMPARED TO SUNITINIB FOR THE FIRST-LINE TREATMENT OF ADVANCED/METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA IN SWITZERLAND
Oniangue-Ndza, C., Schneider, R., Malcolm, B., May, J., Gooden, K.M., Klijn, S., Cakar, E.Volume:
22
Language:
english
Journal:
Value in Health
DOI:
10.1016/j.jval.2019.09.336
Date:
November, 2019
File:
PDF, 381 KB
english, 2019